Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
VJHemOnc Podcast
Exploring Different Drug Combinations in CLL Treatment with Focus on Toxicity and Efficacy Trade-offs
Exploring the trade-off between toxicity and efficacy when using different combinations of inhibitors in CLL treatment, discussing deep responses with undetectable MRD levels, toxicity issues requiring dose reductions, considerations for triplets versus doublets, and the necessity of awaiting randomized clinical trial data for decisions on triplet therapy.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
